Skip to main content

Scleroderma/Raynauds

Treating Obesity is Disease-Modifying (9.4.2026)

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.  New drugs approved, new drugs halted and some drugs out of control. Ready to test your knowlege? Take this week's quiz!

Read Article

NME: New Molecular Entities (8.28.2026)

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com. Take this week's RheumIQ and test your knowledge!

Read Article
The Scleroderma Research Foundation (SRF) will konor John Stamos with the Bob Saget Legacy Award at this year's "Cool Comedy • Hot Cuisine" ceremony that will take place Tuesday, October 13, 2026, at the Beverly Wilshire in Los Angeles. Proceeds will support the SRF https://t.co/VHIpBJrXd4
Dr. John Cush @RheumNow( View Tweet )
Aortic inflammation (Aortopathies) occurs in autoimmune rheumatic diseases (ARD) including Takayasus, #GCA, SLE, RA, AS, SSc, relapsing polychondritis, Cogan’s syndr, Behçet’s, & IgG4-related disease). Dx imaging options: CTA, MRI, & PET/CT. Underlying path may be granulomatous, https://t.co/lKBhEnTcKB
Dr. John Cush @RheumNow( View Tweet )
A Tribute to Thomas A. Medsger Jr., MD (1936–2026) The rheumatology and scleroderma communities mourn the loss of Dr. Thomas A. Medsger Jr., who died August 15, 2026, in Pittsburgh, at age 89. https://t.co/GGC3pZVfJp https://t.co/n0ckoeQ3ZX
Dr. John Cush @RheumNow( View Tweet )

Rheum Scholarship (8.21.2026)

Dr. Cush reviews the news and journal articles from this past week on RheumNow.com; talking about lumbar belts, scholarships and misdiagnosis.

Read Article

A Tribute to Thomas A. Medsger Jr., MD (1936–2026)

The rheumatology and scleroderma communities mourn the loss of Dr. Thomas A. Medsger Jr., who died August 15, 2026, in Pittsburgh, at age 89.

Read Article
SLE & Dermatomyositis rashes maybe classically red or violaceous in Whites,but different in people of color, where erythema often appears brown/violaceous, Gottron papules can be mistaken for "dry skin." This delays dx, especially in anti-MDA5+ RP-ILD, where rash may be the https://t.co/Savx5IOTcG
Dr. John Cush @RheumNow( View Tweet )
Review of CAR-T 29 trials in systemic sclerosis (SSc): 27/29 target CD19 (other CD20, BCMA), 20/29 autologous. Only 2 RCTs; 1 w/ RTX comparator. Most included CREST. Schetts largest series had 6 dcSSc w/ skin/lung improvements. Need fewer & larger multicenter RCTs https://t.co/Me28HbaFhR
Dr. John Cush @RheumNow( View Tweet )

Doubting RS3PE (8.14.2026)

Dr. Jack Cush reviews the news and journal articles this week where RheumNow featured info on cancer, deadly viruses, AI rules, poetry and good moons rising.

Read Article
Biomarker substudy from SENSCIS trial of nintedanib in SSc-ILD shows higher baseline KL-6 levels >1000 U/mL was assoc w/ greater FVC worsening; & decrease in CA-125 was assoc. w/ nintedanib responses. Epithelial cells are primary source of CA-125 in the lung https://t.co/7VJ2UDOKin
Dr. John Cush @RheumNow( View Tweet )
Study of 154 anti-Ku Ab+ pts (51 IMMM, 46 SLE, 30 Sjögrens, 27 Sc) = 60 (39%) had ILD - 75% progressed; more rapidly in males. BUT Ku+ is rare <4%, not specific, without clear clinical implications. Ku is a myositis-assoc Ab (like Ro52/Ro60, U1-RNP, PM/Scl) https://t.co/MHz8mdqDqi
Dr. John Cush @RheumNow( View Tweet )
Arrhythmias in Autoimmune Rheumatic Disease A new review in the Journal of Cardiovascular Development and Disease (Tamirisa et al) synthesizes how SLE, RA, and SSc have an increased risk of arrhythmias and SCD attributable to shared immune pathways. These facts substantiate the https://t.co/j9AW26LE66
Dr. John Cush @RheumNow( View Tweet )

Arrhythmias in Autoimmune Rheumatic Disease

A new review in the Journal of Cardiovascular Development and Disease (Tamirisa et al) synthesizes how systemic lupus erythematosus, rheumatoid arthritis, and systemic sclerosis have an increased risk of arrhythmias and sudden cardiac death attributable to shared immune pathways.

Read Article

Chikungunya Club Meeting (7.24.2026)

Dr. Jack Cush reviews the news, journal reports from the past week on RheumNow.com.

Read Article
EUSTAR scleroderma substudy propensity matched pts Rx w/ JAKi (n 38) vs 180 pts ea Rx w/ MMF, MTX, RTX. 1/3 had dcSSc. 23 AEs in 997 Pt-yrs. JAKi outcomes similar to comparators. JAKi Tx D/C in 39%, FVC stable, skin fibrosis improved (mRSS −1.8) & SJC decreased. No new

Dr. John Cush @RheumNow( View Tweet )

Seronegative RA Disease Activity (7.17.2026)

Dr. Jack Cush reviews the news, journal articles and Gout features from this past week on RheumNow.com.

Read Article

Gout Cavalcade (7.10.2026)

Dr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week. July is Gout: More than Flares month.

Read Article
EULAR26: Reports on Systemic Sclerosis https://t.co/knZZlMYlen https://t.co/0wul0yaw4m
Dr. John Cush @RheumNow( View Tweet )

EULAR26: Reports on Systemic Sclerosis

EurekAlert!

In an oral abstract presentation at EULAR 2026, results were shared from a longitudinal observational analysis of the EUSTAR database. The aim was to characterise organ involvement and disease progression – and time to these events – stratified by having a modified disease activity index (

Read Article

From BiTE to TriTE: Progress of T-cell Engagers in RMDs

The EULAR 2026 Congress in London showcased growing interest in T-cell engagers as a novel strategy to achieve deep B-cell depletion and drug-free remission in refractory rheumatic and musculoskeletal diseases (RMDs). Bispecific T-cell engagers (BiTE) aim to overcome limitations of

Read Article

NK Cells Without a CAR: AB-101 Is Neither CAR-T nor CAR-NK

Much of the meeting came for the next CAR T readout. AB-101 drew attention for a different reason. It depletes B cells by a completely different route.

Read Article
Day 2 Report from EULAR 2026 Day two at EULAR 2026 was jammed with sessions on advances in immune checkpoint inhhbitors (and irAEs), Lupus, Scleroderma, RA and IgG4 related disease. Here are a few of my favorites from Day 2 https://t.co/6KwtkMNLAf https://t.co/Toh4HNZFN5
Dr. John Cush @RheumNow( View Tweet )
Abstr LB0003 Off-the-shelf allogeneic NK cell therapy + rituximab in refractory RA, Sjögren disease, and systemic sclerosis. 31 patients. Outpatient administered. RA at 6 months: 71% ACR50, mean CDAI change −36.8. SSc: 100% rCRISS25 response. SjD: 86% ClinESSDAI responders. https://t.co/60046jgYia
Antoni Chan MD (Prof) @synovialjoints( View Tweet )
Interesting data on the effect of AB-101 + RTX on refractory RA, SSc and SjD. Curious about long term results and potential position in tx strategies LB0006 @RheumNow #EULAR2026 https://t.co/opbh8yGmwO
×